Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03505554
Title A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3)
Acronym CRU3
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Milano Bicocca
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST